Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Laura Mullen
Based on 1 article published since 2009
(Why 1 article?)
||||

Between 2009 and 2019, Laura Mullen wrote the following article about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article A cancer cell-line titration series for evaluating somatic classification. 2015

Denroche, Robert E / Mullen, Laura / Timms, Lee / Beck, Timothy / Yung, Christina K / Stein, Lincoln / McPherson, John D / Brown, Andrew M K. ·Ontario Institute for Cancer Research, Toronto, ON, Canada. rob.denroche@oicr.on.ca. · Ontario Institute for Cancer Research, Toronto, ON, Canada. laura.mullen@oicr.on.ca. · Ontario Institute for Cancer Research, Toronto, ON, Canada. lee.timms@oicr.on.ca. · Ontario Institute for Cancer Research, Toronto, ON, Canada. timothy.beck@oicr.on.ca. · Ontario Institute for Cancer Research, Toronto, ON, Canada. christina.yung@oicr.on.ca. · Ontario Institute for Cancer Research, Toronto, ON, Canada. lincoln.stein@gmail.com. · Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. lincoln.stein@gmail.com. · Ontario Institute for Cancer Research, Toronto, ON, Canada. john.mcpherson@oicr.on.ca. · Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. john.mcpherson@oicr.on.ca. · Ontario Institute for Cancer Research, Toronto, ON, Canada. andrew.brown@oicr.on.ca. ·BMC Res Notes · Pubmed #26708082.

ABSTRACT: BACKGROUND: Accurate detection of somatic single nucleotide variants and small insertions and deletions from DNA sequencing experiments of tumour-normal pairs is a challenging task. Tumour samples are often contaminated with normal cells confounding the available evidence for the somatic variants. Furthermore, tumours are heterogeneous so sub-clonal variants are observed at reduced allele frequencies. We present here a cell-line titration series dataset that can be used to evaluate somatic variant calling pipelines with the goal of reliably calling true somatic mutations at low allele frequencies. RESULTS: Cell-line DNA was mixed with matched normal DNA at 8 different ratios to generate samples with known tumour cellularities, and exome sequenced on Illumina HiSeq to depths of >300×. The data was processed with several different variant calling pipelines and verification experiments were performed to assay >1500 somatic variant candidates using Ion Torrent PGM as an orthogonal technology. By examining the variants called at varying cellularities and depths of coverage, we show that the best performing pipelines are able to maintain a high level of precision at any cellularity. In addition, we estimate the number of true somatic variants undetected as cellularity and coverage decrease. CONCLUSIONS: Our cell-line titration series dataset, along with the associated verification results, was effective for this evaluation and will serve as a valuable dataset for future somatic calling algorithm development. The data is available for further analysis at the European Genome-phenome Archive under accession number EGAS00001001016. Data access requires registration through the International Cancer Genome Consortium's Data Access Compliance Office (ICGC DACO).